Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)

Covid19 Clinical Trial

— CORONA  

Official title:

Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04518735
• Other study ID #: IIBSP-COV-2020-24
• Status: Completed
• Start date: April 1, 2020
• Est. completion date: June 30, 2020

Study information

• Verified date: August 2020
• Source: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents who are admitted to the hospital for COVID-19 compared with patients who do not receive anticoagulants or antiplatelet agents.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1707
• Est. completion date: June 30, 2020
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patient admitted for COVID-19 at the Hospital de la Santa Creu i Sant Pau,

• Positive COVID-19 polymerase chain reaction test

• Length of stay more than 24 hours

Exclusion Criteria:

• No objective diagnose for COVID-19

• Outpatient

• Lenght of stay less than 24hours

Related Conditions & MeSH terms

• Covid19

Intervention

Other:
• Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy

Locations

Country	Name	City	State
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona	Catalonia

Sponsors (1)

Lead Sponsor	Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality		From hospital admission to day 28
Primary	Transfer to the Intensive Care Unit (ICU)		From hospital admission to day 28
Secondary	Thromboembolic complications	Venous thromboembolism, ischemic stroke, myocardial infarction or periferal arterial thrombosis during hospitalization for Covid19	From hospital admission to day 28
Secondary	Major bleeding complications	Any bleeding complication grade 3 or 5 according BARC classification	From hospital admission to day 28